Pancreatic Cancer Research

ResearcherWashington University in St. LouisNo recent work listed

Jessica D. Lindemann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8089-0191; OpenAlex author ID A5046960709. Sources: OpenAlex.

Their work

Papers
4 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2021: 4 papers

Papers 4

  1. Neoadjuvant chemotherapy for non-metastatic pancreatic cancer. First author DOI 10.1002/jhbp.935↗
  2. Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB analysis. First author DOI 10.1016/j.ejca.2021.09.001↗
  3. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and … Co-author DOI 10.1016/j.hpb.2020.09.022↗
  4. Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer". Co-author DOI 10.1097/sla.0000000000004877↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jake E.J. Krige · 4 shared papers, 2021 · strength 0.76
  2. Eduard Jonas · 4 shared papers, 2021 · strength 0.76
  3. Marc M. Bernon · 2 shared papers, 2021 · strength 0.35
  4. Urda K. Kotze · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.